Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15

References

• Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178–84. doi:10.4049/jimmunol.164.8.4178.
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inoges S, Melero I, Berraondo P. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol. 2017;95:347–55. doi:10.1038/icb.2017.6. PMID:28138156.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–8. doi:10.1056/NEJMoa071834. PMID:18003960.
   PubMed Web of Science ®Google Scholar
• Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC medicine. 2012;10:28. doi:10.1186/1741-7015-10-28. PMID:22436374.
   PubMed Web of Science ®Google Scholar
• Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007;25:3712–8. doi:10.1200/JCO.2006.08.8021. PMID:17704420.
   PubMed Web of Science ®Google Scholar
• Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng. 2001;74:288–94. doi:10.1002/bit.1119. PMID:11410853.
   PubMed Web of Science ®Google Scholar
• Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol. 2004;336:1239–49. doi:10.1016/j.jmb.2004.01.007. PMID:15037082.
   PubMed Web of Science ®Google Scholar
• Moga E, Alvarez E, Canto E, Vidal S, Rodriguez-Sanchez JL, Sierra J, Briones J. NK cells stimulated with IL-15or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol. 2008;36:69–77. doi:10.1016/j.exphem.2007.08.012. PMID:17959301.
   PubMed Web of Science ®Google Scholar
• Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395–403. doi:10.1084/jem.180.4.1395. PMID:7523571.
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I. Interleukin-15 in gene therapy of cancer. Curr Gene Ther. 2013;13:15–30. doi:10.2174/156652313804806561. PMID:23157547.
   PubMed Web of Science ®Google Scholar
• Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. 2007;26:503–17. doi:10.1016/j.immuni.2007.03.006. PMID:17398124.
   PubMed Web of Science ®Google Scholar
• Vincent M, Bessard A, Cochonneau D, Teppaz G, Sole V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer. 2013;133:757–65. doi:10.1002/ijc.28059. PMID:23354868.
   PubMed Web of Science ®Google Scholar
• Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, et al. The IL-15-Based ALT-803 Complex Enhances FcgammaRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22:596–608. doi:10.1158/1078-0432.CCR-15-1419. PMID:26423796.
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer research. 2013;73:139–49. doi:10.1158/0008-5472.CAN-12-2660. PMID:23149919.
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, et al. Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PloS One. 2012;7:e52370. doi:10.1371/journal.pone.0052370. PMID:23285013.
   PubMed Web of Science ®Google Scholar
• Kurys G, Tagaya Y, Bamford R, Hanover JA, Waldmann TA. The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15. J Biol Chem. 2000;275:30653–9. doi:10.1074/jbc.M002373200. PMID:10869346.
   PubMed Web of Science ®Google Scholar
• Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002;17:537–47. doi:10.1016/S1074-7613(02)00429-6. PMID:12433361.
   PubMed Web of Science ®Google Scholar
• Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, Plet A, Jacques Y. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. The Journal of biological chemistry. 2006;281:1612–9.
   Google Scholar
• Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015;33:74–82. doi:10.1200/JCO.2014.57.3329. PMID:25403209.
   PubMed Web of Science ®Google Scholar
• Vasquez M, Simoes I, Consuegra-Fernandez M, Aranda F, Lozano F, Berraondo P. Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1. European journal of immunology. 2017;41:1108–1118. doi:10.1002/eji.201646903. PMID:28504304
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999;17:2105–16. doi:10.1200/JCO.1999.17.7.2105. PMID:10561265.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals of surgery. 1989;210:474–84; discussion 84–5. doi:10.1097/00000658-198910000-00008. PMID:2679456.
   PubMed Web of Science ®Google Scholar
• Siegel JP, Puri RK. Interleukin-2 toxicity. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1991;9:694–704. doi:10.1200/JCO.1991.9.4.694. PMID:2066765.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62–8. doi:10.1126/science.aaa4967. PMID:25838374.
   PubMed Web of Science ®Google Scholar
• Marshall D, Sinclair C, Tung S, Seddon B. Differential requirement for IL-2 and IL-15 during bifurcated development of thymic regulatory T cells. J Immunol. 2014;193:5525–33. doi:10.4049/jimmunol.1402144.
   PubMed Web of Science ®Google Scholar
• Fioravanti J, Medina-Echeverz J, Berraondo P. Scavenger receptor class B, type I: a promising immunotherapy target. Immunotherapy. 2011;3:395–406. doi:10.2217/imt.10.104. PMID:21395381.
   PubMed Web of Science ®Google Scholar